These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 12819293)

  • 21. A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta.
    Nicholas JC
    Drugs Aging; 2004; 21(3):187-201. PubMed ID: 14979736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anaemia in diabetic renal failure: is there a role for early erythropoietin treatment in preventing cardiovascular mortality?
    Abaterusso C; Pertica N; Lupo A; Ortalda V; Gambaro G
    Diabetes Obes Metab; 2008 Sep; 10(10):843-9. PubMed ID: 18093210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Managing anaemia and diabetes: a future challenge for nephrologists.
    Ritz E
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi21-5. PubMed ID: 15958822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CREATE: new strategies for early anaemia management in renal insufficiency.
    Macdougall IC; ;
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii13-6. PubMed ID: 12819295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of methoxy polyethylene glycol-epoetin beta in stage 3, 4 or 5 non-dialysis chronic kidney disease.
    Padullés-Zamora N; Comas-Sugrañes D; Pineda-Yuste Mdel M; Jódar-Masanés R; Martínez-Castelao A
    Nefrologia; 2012; 32(2):221-7. PubMed ID: 22421952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary hyperparathyroidism is associated with higher cost of care among chronic kidney disease patients with cardiovascular comorbidities.
    Khan S
    Nephron Clin Pract; 2007; 105(4):c159-64. PubMed ID: 17259740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of an anemia clinic on emergency room visits and hospitalizations in patients with anemia of CKD pre-dialysis.
    Perkins R; Olson S; Hansen J; Lee J; Stiles K; Lebrun C
    Nephrol Nurs J; 2007; 34(2):167-73, 182. PubMed ID: 17486947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time.
    Lu WX; Jones-Burton C; Zhan M; Salzberg DJ; Moore J; Fink JC
    Nephron Clin Pract; 2005; 101(2):c79-86. PubMed ID: 15976508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost comparison of peritoneal dialysis versus hemodialysis in end-stage renal disease.
    Berger A; Edelsberg J; Inglese GW; Bhattacharyya SK; Oster G
    Am J Manag Care; 2009 Aug; 15(8):509-18. PubMed ID: 19670954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study.
    de Francisco AL; Sulowicz W; Klinger M; Niemczyk S; Vargemezis V; Metivier F; Dougherty FC; Oguey D;
    Int J Clin Pract; 2006 Dec; 60(12):1687-96. PubMed ID: 17109676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
    Biesma B; van de Werf PR; Melissant CF; Brok RG
    Lung Cancer; 2007 Oct; 58(1):104-11. PubMed ID: 17601632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].
    Lovcić V; Vujić J; Ivanac Janković R; Basić-Jukić N; Barisić I; Lovcić P; Dzapo M
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():11-6. PubMed ID: 20232547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaemia in diabetes.
    Thomas S; Rampersad M
    Acta Diabetol; 2004 Mar; 41 Suppl 1():S13-7. PubMed ID: 15103543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PAF-acetylhydrolase activity in plasma of patients with chronic kidney disease. Effect of long-term therapy with erythropoietin.
    Papavasiliou EC; Gouva C; Siamopoulos KC; Tselepis AD
    Nephrol Dial Transplant; 2006 May; 21(5):1270-7. PubMed ID: 16421163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The quality of life of dialysis patients treated with recombinant human erythropoietin.
    Auer J; Oliver DO; Winearls CG
    Scand J Urol Nephrol Suppl; 1990; 131():61-5. PubMed ID: 2075472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis.
    Collins AJ; Foley RN; Gilbertson DT; Chen SC
    Clin J Am Soc Nephrol; 2009 Dec; 4 Suppl 1():S5-11. PubMed ID: 19996006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan.
    Furumatsu Y; Nagasawa Y; Hamano T; Iwatani H; Iio K; Shoji T; Ito T; Tsubakihara Y; Imai E
    Nephrol Dial Transplant; 2008 Mar; 23(3):984-90. PubMed ID: 17956890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Guidelines for the treatment of anemia in chronic renal failure].
    Triolo G;
    G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The epidemiology and control of anaemia among pre-ESRD patients with chronic kidney disease.
    McClellan WM; Jurkovitz C; Abramson J
    Eur J Clin Invest; 2005 Dec; 35 Suppl 3():58-65. PubMed ID: 16281960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.